Zusammenfassung
Die experimentelle Erzeugung von Tremor verfolgt im allgemeinen das Ziel, im Tierversuch ein dem menschlichen Parkinsonismus ähnliches Zustandsbild zu reproduzieren. Im Idealfall sollte ein derartiges Syndrom zur pharmakologischen Auswertung von Parkinsonmitteln und für ähnliche Untersuchungen zu verwenden sein.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Abbozzo, G., E. Genazzani et L. Donatelli: L’action du Néoantergan sur les convulsions au Cardiazol et sur la narcose a l’Avertine. Arch. int. Pharmacodyn. 88, 209–222 (1951).
Abood, L. G., E. Kun and E. M. K. Geiling: Phosphorylated intermediates of chronically and acutely morphinized rats. J. Pharmacol. exp. Ther. 98, 373–379 (1950).
—, and E. B. Sigg: Correlation between experimental catatonia and inhibition of phosphorylation. Fed. Proc. 14, 1 (1955).
Ahmed, A., P. B. Marshall and D. M. Shepherd: Pharmacology of tremor-producing ammo alcohols. J. Pharm. (Lond.) 10, 672–682 (1958).
Albertoni, P.: Untersuchungen über die Wirkung einiger Arzneimittel auf die Erregbarkeit des Großhirns nebst Beiträgen zur Therapie der Epilepsie. Pflügers Arch. ges. Physiol. 15, 248–288 (1882).
Albus, G.: Tierexperimentelle Untersuchungen über die Weckwirkung handelsüblicher Analeptica unter besonderer Berücksichtigung von Cardiazol und Coramin. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 182, 471–476 (1936).
Alema, G., and C. Sergio: On the influence of some pharmacological substances upon the experimental catatonia produced by bulbocapnine, reserpine and chlorpromazine in rats. In: S. Garattini and V. Ghetti: Psychotropic Drugs, p. 168–170. Elsevier Publishing Company 1957.
Amsler, C.: Zur Pathogenese der Gewöhnung an Morphin. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 161, 233–246 (1931).
Armstrong, M. D., and N. L. Low: Phenylketonuria VIII. Relation between age, serum phenylalanine level, and phenylpyruvic acid excretion. Proc. Soc. exp. Biol. (N. Y.) 94, 142–146 (1957).
Arnold, A., and C. A. Elvehjem: Is running fits a deficiency disease? J. Amer. vet. med. Ass. 95, 303–308 (1939).
Arrigoni-Martelli, E., e M. Kramer: Studio farmacologico di un nuovo derivato feno-tiazinico: la perfenazina. Arch. int. Pharmacoyn. 119, 311–333 (1959).
Auerbach, V. H., and H. A. Waisman: The metabolism of aromatic amino acids in leukemic rats. Cancer Res. 18, 536–542 (1958).
— — and L. B. Wyckoff, jr.: Phenylketonuria in the rat associated with decreased temporal discrimination learning. Nature (Lond.) 182, 871–872 (1958).
Axmacher, F.: Über erregende und analeptische Eigenschaften des Methylimidazols nebst Vergleich mit der Wirkung von Cardiazol und Coramin. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 183, 478–499 (1936).
Azima, H., and B. Grad: Production of a permanent state of excitation in mice and rats with β,β-iminodipropionitrile. Fed. Proc. 15, 6 (1956).
Bachem, C.: Das Verhalten des Veronals (Veronalnatriums) im Tierkörper bei einmaliger und bei chronischer Darreichung. Naunyn-Schmiddeberg’s Arch. exp. Path. Pharmak. 63, 228–241 (1910).
Bachhuber, T. E., J. J. Lalich, D. M. Angevine, E. D. Schilling and F. M. Strong: Lathyrus factor activity of beta-aminopropionitrile and related compounds. Proc. Soc. exp. Biol. (N. Y.) 89, 294–297 (1955).
Bárány, E.: The influence of the electrode arrangement in the determination of drug action by means of electrical convulsive thresholds. Arch. int. Pharmacodyn. 73, 189–192 (1946).
—, and E. Stein-Jensen: The mode of action of anticonvulsant drugs on electrically induced convulsions in the rabbit. Arch. int. Pharmacodyn. 73, 1–47 (1946).
Barbour, H. G., J. A. Porter and J. M. Seelye: Morphinism as a metabolic stimulant. J. Pharmac. exp. Ther. 65, 332–342 (1939).
Barlow, O. W.: The relative efficiency of a series of analeptics as antidotes to sublethal and lethal dosages of pentobarbital, chloral hydrate, and tribromethanol (“avertin”). J. Pharmacol. exp. Ther. 55, 1–23 (1935).
—, and J. R. Lewis: Toxicology and addiction liability of meperidine (demerol) in experimental animals. J. Pharmacol. exp. Ther. 103, 147–152 (1951).
Baruk, H., et H. de Jong: Études sur la catatonie expérimentale. L’épreuve de la bulbo-capnine chez divers animaux avec et sans néopallium. Rev. neurol. 2, 532–541 (1929).
Batelli, M. F.: Production de l’accès épileptiforme par les courants électriques industriels. C. R. Soc. Biol. (Paris) 55, 883 (1903).
Bauthier, J., et H. Vandersmissen: Antagonisme entre le carbamate de propynyl-cyclo-hexanol et deux stimulants nerveux centreaux. Arch. int. Pharmacodyn. 119, 258–263 (1959).
Beer, A. G.: Beiträge zur Pharmakologie des extrapyramidalen Systems. I. Mitteilung: Die Wirkung des Harmins bei Katzen mit intaktem Nervensystem. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 193, 377–392 (1939a).
— Beiträge zur Pharmakologie des extrapyramidalen Systems. IL Mitteilung: Die Wirkung des Harmins bei Katzen ohne Neocortex. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 193, 393–407 (1939b).
Bein, H. J., F. Gross, J. Tripod U. R. Meier: Experimentelle Untersuchungen über „Serpa-sil“(Reserpin), ein neues, sehr wirksames Rauwolfiaalkaloid mit neuartiger zentraler Wirkung. Schweiz. med. Wschr. 83, 1007–1012 (1953).
Belford, J., and D. C. Bonnycastle: The effects of some anticonvulsant agents upon agene-induced convulsions in dogs. J. Pharmacol. exp. Ther. 99, 325–328 (1950).
Bentley, H. R., E. E. Mc Dermott, J. Pace, J. K. Whitehead and T. Moran: Action of nitrogen trichloride on proteins: Progress in the isolation of the toxic factor. Nature (Lond.) 163, 675–676 (1949a).
— — — — — Action of nitrogen trichloride (“agene”) on proteins: Isolation of cristalline toxic factor. Nature (Lond.) 164, 438–439 (1949b).
— — — — — Toxic factor from “agenized” proteins: Methionine as the essential reactant. Nature (Lond.) 165, 150–151 (1950a).
— — — and J. K. Whitehead: Action of nitrogen trichloride on proteins: A synthesis of the toxic factor from methionine. Nature (Lond.) 165, 735 (1950b).
Bertschik, G.: Über Wiederherstellung der infolge von Gewöhnung an Morphin aufgehobenen Cocainanästhesie der Hornhaut bzw. über Aufhebung derselben bei nicht morphingewöhnten Tieren durch Milch. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 177, 56–59 (1935).
Bianchi, C: Reserpine and serotonin in experimental convulsions. Nature (Lond.) 179, 202–203 (1957).
—, and J. Franceschini: Experimental observations on Haffner’s method for testing analgesic drugs. Brit. J. Pharmacol. 9, 280–284 (1954).
Biberfeld, J.: Zur Kenntnis der Gewöhnung. III. Über experimentelle Gewöhnung an Schlafmittel. Biochem. Z. 92, 198–210 (1918).
Bickis, I. J., J. P. Kennedy and J. H. Quastel Phenylalanine inhibition of tyrosine metabolism in the liver. Nature (Lond.) 179, 1124–1126 (1957).
Biehler, W.: Krampfgrenze und Krampfhemmung. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 178, 693–699 (1935).
Bikeles, G., u. L. Zbyszewski: Über Erregbarkeit der Großhirnrinde und Auslösbarkeit von Rindenepilepsie unter Einfluß von Schlafmitteln wie nach Verabreichung größerer Bromgaben. Pflügers Arch. ges. Physiol. 158, 235–251 (1914).
Blockus, L. E., and G. M. Everett: Tremor producing drug 1,4 dipyrrolidino-2-butyne (“Tremorme”). Fed. Proc. 16, 283 (1957).
Blum, B., and S. Zacks: Analysis of the relationship between drug-induced convulsions and mortality in rats. J. Pharmacol. exp. Ther. 124, 350–356 (1958).
Borek, E., A. Brecher, G. A. Jervis and H. Waelsch: Oligophrenia phenylpyruvica. II. Constancy of the metabolic error. Proc. Soc. exp. Biol. (N. Y.) 75, 86–89 (1950).
Bouma, J.: Über Gewöhnungsversuche mit Kodein. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 50, 353–360 (1903).
Bovet, D., and V. G. Longo: The action on nicotine-induced tremors of substances effective in parkinsonism. J. Pharmacol. Ther. 102, 22–30 (1951).
Boyd, E. M.: Chlorpromazine tolerance and physical dependence. J. Pharmacol. exp. Ther. 128, 75–78 (1960).
Brock, N., D. Lorenz U. H. Veigel: Beitrag zur Wirkung von Antihistamin-Substanzen. II. Zur Pharmakologie des Systral. Arzneimittel-Forsch. 4, 262–268 (1954).
Brodie, B. B., L. C. Mark, P. A. Lief, E. Bernstein and E. M. Papper: Acute tolerance to thiopental. J. Pharmacol. exp. Ther. 102, 215–218 (1951).
Broom, W. A., M. R. Gurd and G. L. M. Harmer: Effect of diet on toxicity to rabbits of the toxic factor from “agenized” flour. Nature (Lond.) 167, 772–773 (1951).
van der Brook, M. S., and G. E. Cartland: J. Pharmacol. exp. Ther. 80, 119 (1944); zit. bei Ch. M. Gruber and G. F. Keyser: J. Pharmacol. exp. Ther. 86, 186–196 (1946).
Brown, W. C.: Unveröffenthcht. Zit. bei Swinyard U. Mitarb. (1952).
— D. O. Schiffman, E. A. Swinyard and L. s. Goodman: Comparative assay of antiepileptic drugs by “psychomotor” seizure test and minimal electroshock threshold test. J. Pharmacol. exp. Ther. 107, 273–283 (1953).
Brücke, F. Th.: Beiträge zur Pharmakologie des Bulbocapnins. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 179, 504–523 (1935).
— Das Wesen der Bulbocapninstarre. Naunyna-Schmiedeberg’s Arch. exp. Path. Pharmak. 182, 324–330 (1936).
Bruns, F., F. Hahn U. W. Schild: Untersuchungen zur Pharmakologie der Wärmeregulation. I. Mitteilung. Über den Wirkungsmechanismus und die Angriffspunkte der Narkotika, Krampfgifte und Antipyretika. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 209, 104–129 (1950).
Buchman, E. F., and C. P. Richter: Abolition of bulbocapnine catatonia by cocaine. A. M. A. Arch. Neurol. Psychiat. 29, 499–503 (1933).
Büch, O.: Zur antikonvulsiven Wirkung des kurzwirkenden Injektionsnarkoticums 2-Methoxy-4-allylphenoxyessigsäure-N,N-diäthylamid (G 29505). Arch. int. Pharmacodyn. 114, 439–445 (1958).
Burns, R. H., D. A. Mc Carthy, G. A. Deneau and M. H. Seevers: Comparison of dose dependent effects of nalorphine with those of levallorphan in production of graded abstinence in morphine dependent monkeys. Fed. Proc. 17, 355 (1958).
Butler, J. A. V., and G. L. Mills: Concentration of the toxic substance from “agenized” flour. Nature (Lond.) 163, 835–836 (1949).
Butler, T. C., C. Mahaffee and W. J. Waddell: Phenobarbital: Studies of elimination, tolerance, and dosage schedules. J. Pharmacol. exp. Ther. 111, 425–435 (1954).
Cahen, R.: Hyposensibilité cellulaire acquise vis-a-vis de la morphine. Arch. int. Pharmacodyn. 53, 426–456 (1936).
Cahen, R. L.: Action of nicotinic stimulant agents on rabbit skeletal muscle. I. Nicotine and acetylcholine. Proc. Soc. exp. Biol. (N. Y.) 84, 474–476 (1953).
— E. Groskinsky and P. Parisek: Comparative effect of morphine and morphine derivatives on chemically induced convulsant seizures. J. Pharmacol. exp. Ther. 119, 137 (1957).
—, and T. E. Lynes: Nicotinolytic drugs. I. Drugs inhibiting nicotine-induced tremors. J. Pharmacol. exp. Ther. 103, 44–53 (1951).
— — Nicotinolytic drugs. II. Action of adrenergic blocking agents on nicotine-induced tremors. J. Pharmacol. exp. Ther. 107, 424–436 (1953).
Camp, W. J. R.: The pharmacology of cardiazol. J. Pharmacol. exp. Ther. 33, 81–92 (1928).
Campbell, P. N., T. S. Work and E. Mellanby: Isolation of a crystalline toxic factor from agenized wheat flour. Nature (Lond.) 165, 345–346 (1950).
Carmichael, E. B., and L. C. Posey: Observations on effect of repeated administration of nembutal in guinea pigs. Proc. Soc. exp. Biol. (N. Y.) 30, 1329–1330 (1933).
Carter, R. L., and A. Wikler: Use of N-allylnormorphine in early demonstration of physical dependence on potent analgesic in dogs. Fed. Proc. 13, 342 (1954).
— — Chronic meperidine intoxication in intact and chronic spinal dogs. Fed. Proc. 14, 325 (1955).
Chakravarti, M.: A quantitative comparison of different analeptics. J. Pharmacol. exp. Ther. 67, 153–174 (1939).
Chen, G.: The anti-tremorine effect of some drugs as determined by Haffner’s method of testing analgesia in mice. J. Pharmacol. exp. Ther. 124, 73–76 (1958).
—, and B. Bohner: A study of the neuropharmacologic properties of certain convulsants, anticonvulsants and reserpine. J. Pharmacol. exp. Ther. 117, 142–147 (1956).
— — A study of central nervous system stimulants. J. Pharmacol. exp. Ther. 123, 212–215 (1958).
— — and C. R. Ensor: Evaluation of five methods for testing anticonvulsant activities. Proc. Soc. exp. Biol. (N. Y.) 87, 334–339 (1954b).
— C. R. Ensor and B. Bohner: A facilitation action of reserpine on the central nervous system. Proc. Soc. exp. Biol. (N. Y.) 86, 507–510 (1954a).
— — — Anticonvulsant effects of certain CNS depressants on convulsions induced by strychnine, metrazol or caffeine. Arch. int. Pharmacodyn. 104, 333–338 (1956).
Cheymol, J., et J. Thuillier: Anticonvulsants et crises toxiques chez la souris. Arch. int. Pharmacodyn. 83, 593–601 (1950).
Chin, L., and E. A. Swinyard: Tolerance and withdrawal hyperexcitability induced in mice by chronic administration of phenaglycodol. Proc. Soc. exp. Biol. (N. Y.) 97, 251–254 (1958).
Chu, Wei-Chang, and R. L. Driver: Effects of some old and proposed anticonvulsants on the threshold for electrical convulsions. Proc. Soc. exp. Biol. (N. Y.) 64, 245–248 (1947).
Chusid, J. G., L. M. Kopeloff and N. Kopeloff: Reserpine (Serpasil) effects on epileptic monkeys. Proc. Soc. exp. Biol. (N. Y.) 88, 276–277 (1955).
Cochin, J., and J. A. Axelrod: Analgesic response and N-dealkylation of narcotics after short-term administration of morphine, nalorphine and normorphine. Fed. Proc. 17, 359 (1958).
— — Biochemical and pharmacological changes in the rat following chronic administration of morphine, nalorphine and normorphine. J. Pharmacol. exp. Ther. 125, 105–110 (1959).
— C. C. Gruhzit, L. A. Woods and M. H. Seevers: Further observations on addiction to methadon in the monkey. Proc. Soc. exp. Biol. (N. Y.) 69, 430–431 (1948).
— J. Haggart, L. A. Woods and M. H. Seevers: Plasma levels, urinary and fecal excretion of morphine in non-tolerant and tolerant dogs. J. Pharmacol. exp. Ther. 111, 74–83 (1954).
—, and C. Kornetsky: A comparison of the effects of chronic morphine administration on analgesic response and swimming time in the rat. J. Pharmacol. exp. Ther. 122, 12A–13A (1958).
Cole, J., and P. Glees: Ritalin as an antagonist to reserpine in monkeys. Lancet 270, 338 (1956).
Conrad, E. A., G. H. Armstrong and J. M. Little: Factors affecting seizures in mice induced by the oral administration of pentylenetetrazol. J. Pharmacol. exp. Ther. 122, 14 (1958).
Courvoisier, S., R. Ducrot, J. Fournel et L. Julou: Propriétés pharmacodynamiques générales de la prochlorpémazine (6. 140 R.P.). C. R. Soc. Biol. (Paris) 151, 1144–1148 (1957b).
— — et L. Julou: Nouveaux aspects expérimentaux der l’activité centrale des dérivés de la phénothiazine. In: S. Garattini and V. Ghetti: Psychotropic Drugs. p. 373–391. Elsevier Publishing Company, 1957 (a).
Dahlbom, R., T. Edlund, T. Ekstrand and A. Katz: The ability of some phenothiazine derivatives to inhibit nicotine-induced tremors. Arch. int. Pharmacodyn. 90, 241–250 (1952).
Dallemagne, M. J.: L’accoutumance expérimentale a l’évipan et au numal. Arch. int. Pharmacodyn. 65, 52–62 (1941).
Dasler, W.: Production by semicarbazide of gross skeletal changes in rats similar to osteola-thyrism. Proc. Soc. exp. Biol. (N. Y.) 97, 112–114 (1958).
Davenport, V. D., and H. W. Davenport: J. Nutr. 36, 139 (1948); zit. bei Woodbury and Davenport (1952).
Davis, H., C. H. Hine, M. W. Neal, H. E. Christensen and F. J. Murphy: Some pharmacologic comparisons of l-ethoxy-3-isopropoxy-propane-2-ol and 3-(2′-methylphenoxy)-propane-l,2-diol (Myanesin). Arch. int. Pharmacodyn. 89, 145–159 (1952).
Decsi, L., M. Várszegi and J. Méhes: Tolerance to tremorine. J. Pharm. (Lond.) 13, 127 (1961).
de Jong, H.: Über Bulbocapnin-Katalepsie. Klin. Wschr. 1, 684–685 (1922).
— Experimental catatonia in a chimpanzee. Proc. Soc. exp. Biol. (N. Y.) 41, 395–396 (1939).
—, et H. Baruk: Étude comparative expérimentale et clinique des manifestations du syndrome catatonique. Rev. neurol. 1, 21–34 (1929a).
— — Études sur la catatonie expérimentale. L’épreuve de la bulbocapnine chez les singes. Comparaison des stades de l’intoxication bulbocapninique avec les aspects de la Catatonie humaine. Rev. neurol. 2, 541–547 (1929b).
— — La Catatonie Expérimentale par la Bulbocapnine. Étude physiologique et clinique. Paris: Masson et Cie. 1930.
—, and E. Chase: Emontial expressions of cats in bulbocapnine catatonia. J. nerv. ment. Dis. 98, 478–484 (1934).
de Jong, H. H.: Experimental Catatonia. A General Reaction-Form of the Central Nervous System and Its Implications for Human Pathology. Baltimore: Wilhams & Wilkins Company 1945.
de Jongh, D. K.: An apparatus for the induction of supramaximal electroshock seizures in groups of ten mice. Acta physiol. pharmacol. neerl. 6, 511–514 (1957).
—, and E. G. van Proosdij-Hartzema: Anticonvulsant activity of a series of substituted acetamides and thioacetamides. Acta physiol. pharmacol. neerl. 5, 485–488 (1957).
Delay, Denkier, Ropert, Beck, Barande et Eurieult: Presse méd. 67, 123 (1959) ; zit. bei M. W. Parkes: Tranquillizers. In: G. P. Ellis and G. B. West: Progress in medicinal chemistry. Vol. I., p. 72–131. Butterworths 1961.
Delay, J., P. Pichot, J. Thuillier et J.-P. Marquiset: Action de I’aminodipropionitrile sur le comportement moteur de la souris blanche. C. R. Soc. Biol. (Paris) 146, 533–534 (1952).
Deneau, G., J. Kissel and M. H. Seevers: Influence of frequency of administration on development of physical dependence to analgesics in monkey. Fed. Proc. 13, 347 (1954).
Deneau, G., and M. H. Seevers: Thresholds of electrical excitability and electrograms in monkeys with permanently implanted cortical and subcortical electrodes during a cycle of morphine “addiction”. Fed. Proc. 17, 362 (1958).
Detrick, L. E., and C. H. Thienes: Tissue hydration during morphine addiction and withdrawal in rats on low calcium diet and on high calcium diet with parathyroid hormone injection. Arch. int. Pharmacodyn. 66, 130–137 (1941).
Deuel, H. J., W. H. Chambers and A. J. Milhorat: J. biol. Chem. 69, 249 (1926); zit. bei Gruber, Ch. M., and G. F. Keyser: J. Pharmacol. exp. Ther. 86, 186–196 (1946).
Dietrich, S., u. H. Ebster: Über den Einfluß von Muskelkrämpfen auf die Gase und die Reaktion des Blutes nebst einer Bemerkung über den Mechanismus des Strychnintodes. Arch. exp. Path. Pharmak. 129, 339–353 (1928).
Divry, et Evrard: Reserches sur certaines substances antagonistes de la bulbocapnine. J. belge Neurol. Psychiat. 34, 506–523 (1934).
Dongen, K. van: Beiträge zur Frage der Morphingewöhnung. Pflügers Arch. ges. Physiol. 162, 54–66 (1915).
Dundee, J. W., H. J. Price and R. D. Dripps: Brit. J. Anaesth. 28, 344 (1956), zit. bei Maynert, E. W. and G. I. Klingman: J. Pharmacol. exp. Ther. 128, 192–200 (1960).
Eddy, N. B.: The effect of the repeated administration of diethyl barbituric acid and of cyclohexenyl-ethyl barbituric acid. J. Pharmacol. exp. Ther. 37, 261–271 (1929).
—, and J. G. Reid: Studies of morphine, codeine and their derivatives. VII. Dihydromorphine (paramorphan), dihydromorphinone (dilaudid), and dihydrocodeinone (dicodid). J. Pharmacol. exp. Ther. 52, 468–493 (1934).
Egmond, A. A. J. van: Über die Wirkung des Morphins auf das Herz. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 65, 197–213 (1911).
Ehrlich, P.: Chemotherapeutische Trypanosomen-Studien. Berl. klin. Wschr. 44, 280–283 (1907).
Eichholtz, F., H. Veigel u. J. Seeman: Der Antagonismus von convulsiven und spasmo-lytischen Substanzen. Naunyn-Schmiedeberg’s Aich. exp. Path. Pharmak. 76, 127–140 (1948).
Elithorn, A., D. M. Johnson and M. A. Crosskey: Effects of agenized flour on man. Lancet 1949 I, 143.
Essig, C. F., and J. D. Ainslie: Addiction to meprobamate (equanil, miltown). J. Amer. med. Ass. 164, 1382 (1957).
—, and A. Wikler: Prevention of barbiturat withdrawal in cats by cerebral electrostimulation. Fed. Proc. 15, 59 (1956).
Ettinger, G. H.: The duration of anaesthesia produced in the dog by the repeated administration of dial and nembutal. J. Pharmacol. exp. Ther. 63, 82–87 (1938).
Everett, G. M.: Tremor produced by drugs. Nature (Lond.) 177, 1238 (1956a).
— A study of tremor and the Parkinson-like syndrome produced by 1,4-dipyrrolidino-2-butyne, “Tremorine”. XXth International Physiological Congress, Brussels, 1956, Abstracts of Communications, p. 281–282 (b).
— L. E. Blockus and I. M. Shepperd: Tremor induced by tremorine and its antagonism by anti-parkinson drugs. Science 124, 79 (1956a).
— — — and J. E. Toman: Production of tremor and a Parkinson-like syndrome by 1–4 dipyrrolidino-2-butyne, “Tremorine.” Fed. Proc. 15, 420–421 (1956b).
—, and R. K. Richards: Pharmacological studies of phenacetylurea (phenurone), an anticonvulsant drug. J. Pharmacol. exp. Ther. 106, 303–313 (1952).
Evrard, E., U. E. A. Spiegel: Durchbrechung der Bulbocapnin-Katalepsie durch Cocain. Z. ges. Neurol. Psychiat. 138, 197–202 (1932).
Faust, E. S.: Über die Ursachen der Gewöhnung an Morphin. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 44, 217–238 (1900).
Fazio, C., and U. Sacchi: Experimental catalepsy produced by substances introduced into subarachnoid spaces and ventricles. In: S. Garattini and V. Ghetti: Psychotropic Drugs. Elsevier Publishing Company, 1957, p. 104–109.
Feer, H., U. P. G. Waser: Beziehungen zwischen der chemischen Struktur und der antikonvulsiven Wirksamkeit einiger bromierter Hydantoine. Helv. physiol. pharmacol. Acta 14, 29–36 (1956).
Feldberg, W., and S. L. Sherwood: Behaviour of cats after intraventricular injections of eserine and DEP. J. Physiol. (Lond.) 125, 488–500 (1954).
— — — Injections of bulbocapnine into the cerebral ventricles of cats. Brit. J. Pharmacol. 10, 371–374 (1955).
Ferraro, A., and E. Barrera: Experimental Catalepsy. Utica, N. Y.: New York States Hospitals Press. 1932.
Finnegan, J. K., H. B. Haag, P. S. Larson and M. L. Dreyfuss: Observations on the comparative actions of 6-dimethylamino-4,4-diphenyl-3-heptanone (amidone) and mor-phine. J. Pharmacol. exp. Ther. 92, 269–276 (1948).
Fischer, J., Z. Lodin and J. Koloušek: A contribution to the histopathology of experimental seizures evoked by methionine sulfoximine (MSI). Proc. First Internat. Congr. of Neurol. Sci., Brusseles, Vol. III, p. 610–612 (1957).
Fitch, R. H.: An experimental study of tolerance to barbiturates. J. Pharmacol. exp. Ther. 39, 266–267 (1930).
Flury, F.: Beiträge zur Pharmakologie der Steppenraute (Peganum Harmala). Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 64, 105–125 (1911).
Formanek, K., u. A. Lindner: Einfluß der Außentemperatur auf die Wirkung von Krampfgiften. Wien. med. Wschr. 110, 461–463 (1960).
Fränkel, S.: Chemie und Pharmakologie des Haschisch. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 49, 266–284 (1903).
Fraser, H. F., and H. Isbell: Chronic intoxication of dogs with sodium barbital. Fed. Proc. 13, 355 (1954a).
— — Abstinence syndrome in dogs after chronic barbiturate medication. J. Pharmacol. exp. Ther. 112, 261–267 (1954b).
Fritsch, G., U. E. Hitzig: Über die elektrische Erregbarkeit des Großhirns. Virchows Arch. path. Anat. 1870, p. 300; zit. bei Schilf.
Fröhlich, A., U. H. H. Meyer: Über die Dauerverkürzung der gestreiften Warmblütermuskeln. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 87, 173–188 (1920).
Frommel, Ed., et I.T. Beck: Étude comparative de la marge thérapeutique entre les doses convulsivantes et mortelles de la coramine, du cyclitron, du cardiazol, de la strychnine, de la Picrotoxine et de la caféine. Schweiz. med. Wschr. 78, 1176–1178 (1948).
— C. Radouco, Ph. Gold, G. Greder, D. Melkonian, L. Strassberger, F. Vallette et M. Ducommun: Étallonnage de la toxicité et de la puissance de diverses substances anti-convulsivantes sur l’animal soumis au choc chimique. Arch. int. Pharmacodyn. 92, 44–70 (1952).
Gardner, A. F.: Experimental lathyrism. Review of the literature. Amer. J. clin. Nutr. 7, 312–323 (1959).
Garello, L., e G. Dolce: Boll. Soc. ital. biol. sper., Sezione di Genova, 1956; zit. bei C. Fazio and U. Sacchi (1957).
Gerlich, N.: Experimentelle Studien über die Beziehungen zwischen Schilddrüse und Krampfbereitschaft. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 207, 159–172 (1949).
Gessner, O.: Vergleichend-pharmakologische Untersuchungen über die analeptische Wirkung von Salamandrin, Pikrotoxin und Cardiazol. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 205, 1–20 (1948).
Ginzel, K. H.: Vergleichende Untersuchung einiger antikonvulsiv wirksamer Glyzerinäther. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 212, 331–338 (1951).
Girndt, O., u. G. Schaltenbrand: Beiträge zur Pharmakologie der Körperstellung und der Labyrinthreflexe. XVI. Mitteilung. Die Wirkung des Bulbocapnins auf Thalamuskatzen. Pflügers Arch. ges. Physiol. 209, 653–663 (1925).
Gold, H.: On morphine habituation: Tolerance to the stimulant action of morphine. J. Pharmacol. exp. Ther. 35, 355–362 (1929).
Goldin, A., H. A. Noe, B. H. Landing, D. M. Shapiro and B. Goldberg (with the technical assistance of R. A. Fugmann, M. A. Miller and A. J. Fisk): A neurological syndrome induced by administration of some chlorinated tertiary amines. J. Pharmacol. exp. Ther. 94, 249–261 (1948).
Goodman, L. S., M. S. Grewal, W. C. Brown and E. A. Swinyard: Comparison of maximal seizures evoked by pentylene-tetrazol (Metrazol) and electroshock in mice, and their modification by anticonvulsants. J. Pharmacol. exp. Ther. 108, 168–176 (1953a).
— E. A. Swinyard and J. E. Toman: Effects of 1(+) glutamic acid and other agents on experimental seizures. A. M. A. Arch. Neurol. Psychiat. 56, 20–29 (1946).
— — W. C. Brown, D. O. Schiffman, M. S. Grewal and E. L. Bless: Anticonvulsant properties of 5-phenyl-5-ethyl-hexahydropyrimidine-4,6-dione (mysoline), a new anti-epileptic. J. Pharmacol. exp. Ther. 108, 428–436 (1953b).
— — — — Anticonvulsant properties of 5,5-diphenyl-tetrahydro-glyoxaline-4-one (SKP No. 2599). J. Pharmacol. exp. Ther. 109, 403–410 (1953c).
— J. E. P. Toman and E. A. Swinyard: Anticonvulsant drugs: Mechanisms of action and methods of assay. Arch. int. Pharmacodyn. 78, 144–162 (1949).
Gottlieb, R.: Vergleichende Messungen über die Gewöhnung des Atemzentrums an Morphin, Dicodid und Dilaudid. Münch. med. Wschr. 73, 595 (1926).
Greig, M. E., R. A. Walk and A. J. Gibbons: Bulbocapnine catatonia in mice. Fed. Proc. 17, 373 (1958).
Gros, O., u. H. T. A. Haas: Der Antagonismus der Narkotica gegen Cardiazol. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 182, 348–362 (1936).
Gross, E. G., and R. M. Featherstone: Studies with tetrazole derivatives. I. Some pharmacologic properties of aliphatic substituted pentamethylene tetrazole derivatives. J. Pharmacol. exp. Ther. 87, 291–298 (1946).
—, and I. H. Pierce: Effect of morphine on the oxygen consumption of brain tissue in the rat. J. Pharmacol. exp. Ther. 53, 156–168 (1935).
Gruber, Ch. M., and G. F. Keyser: A study on the development of tolerance and cross tolerance to barbiturates in experimental animals. J. Pharmacol. exp. Ther. 86, 186–196 (1946).
Grüneberg, H.: The Genetics of the Mouse. Cambridge Univerity Press, 1943.
Grüninger, U.: Die Wirkung einmaliger und verteilter Morphingaben auf die Atmung des Kaninchens. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 126, 77–86 (1927).
Gutierrez-Noriega, Rotondo y Alarco: An. Fac. Med. (Lima) 21, 263 (1939); zit. in „Cardiazol“, Knoll A.-G. Chemische Fabriken, Ludwigshafen am Rhein, 1951.
Haas, H., U. W. Klavehn: Über 3-Piperidino-l-phenyl-l-bicycloheptenyl-propanol-(l) (Akineton). Naunyn-Schmiedeberg’s Arch. exp. Pharmak. 226, 18–35 (1955).
Haeffer, F., U. F. Wind: Über Gewöhnung an Narkotika. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 116, 125–134 (1926).
Hahn, F.: Vergleichende Untersuchungen über die Krampf- und Blutdruckwirkung einiger Analeptica an dekapitierten Katzen. Naunyn-Schmiedeberg–s Arch. exp. Path. Pharmak. 198, 509–527 (1941).
— Untersuchungen über die Angriffspunkte von Cardiazol und Coramin. I. Über die Krampfund Weckwirkung. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 205, 552–562 (1948).
— Untersuchungen über die Angriffspunkte von Cardiazol und Coramin. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 208, 29–31 (1949).
— Analeptics. Pharmacol. Rev. 12, 447–530 (1960).
Hanna, C.: A demonstration of morphine tolerance and physical dependence in the rat. Arch. int. Pharmacodyn. 124, 326–329 (1960).
Hara, S.: Pharmacological studies in the functions of the extrapyramidal system. Report No. 1. Jap. J. Pharmacol. 2, 127–138 (1953).
—, and K. Kawamori: Pharmacological studies on the function of the extrapyramidal system. Report No. 2. Mechanism of the appearance of tremor due to extrapyramidal poisons. Jap. J. Pharmacol. 3, 149–156 (1954).
—, and Mori: Jap. J. med. Sci. Pharmacol. 7, 78–79 (1933); zit. bei A. G. Beer (1939a).
Harned, B. K., R. W. Cunningham, M. C. Clark, C. H. Hine, M. M. Kane, F. H. Smith jr., R. E. Vessey, N. N. Yuda and F. W. Zabransky: The pharmacology of N-benzyl-beta-chloropropionamide (hibicon), a new anticonvulsant. J. Pharmacol. exp. Ther. 107, 403 bis 423 (1953).
Harris, H.: Human Biochemical Genetics. Cambridge University Press, 1959.
Hartmann, H. A., and H. F. Stich: Psychopathologic symptoms induced by bis-beta-amino-propionitrile. Science 125, 445 (1957).
Hatcher, R. A., and H. Gold: The mechanism of morphine habituation. J. Pharmacol. exp. Ther. 35, 257–279 (1929).
Hausmann, W.: Zur Kenntnis der chronischen Morphinvergiftung. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 52, 315–325 (1905).
Henry, G. W.: Experimental catatonia in birds. Psychiat. Quart. 5, 68–81 (1931).
—, and H. de Jong: A comparative study of the action of bulbocapnine and some other drugs in producing catatonic states. Acta psychiat. (Kbh.) 5, 463–471 (1930).
Helaers, E.: Contribution a l’étude de divers analeptiques respiratoires chez le lapin normal ou intoxiqué par la morphine ou le somnifène. Arch. int. Pharmacodyn. 35, 221–265 (1929).
Herken, H.: Änderungen von Zellfunktionen im Nervensystem durch Hexachlorcyclohexan. (Untersuchungen am Warmblütler.) Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 211, 143–152 (1950).
— Eingriffe am Nervensystem mit Hexachlorcyclohexan. Arzneimittel-Forsch. 1, 356–359 (1951).
Herrmann, O.: Eine biologische Nachweismethode des Morphins. Biochem. Z. 39, 216–231 (1912).
Hewetson, H. R.: Vet. Rec. 48, 1202 (1936); zit. bei Newell U. Mitarb. (1948).
Heymans, C., and J. J. Estable: On new nicotinolytic compounds. Science 109, 122 (1949).
— — et S. Castillo de Bonneveaux: Sur la pharmacologie de la phénothiazinyl-éthyl-diéthylamine (2987 R.P.). Arch. int. Pharmacodyn. 79, 123–138 (1949a).
— — — Nicotinolytic action of diethylaminoethylphenothiazine (2987 R.P. or Diparcol). Arch. int. Pharmacodyn. 79, 185–188 (1949b).
Heymans, C., et G. R. de Vleeschhouwer: Actions pharmacologiques de l’ester diéthyl-aminoéthylique de l’acide phényl-cyclopentane-carboxylique (Parpanit). Arch. int. Pharmacodyn. 75, 307 bis 324 (1948).
Hildebrandt, F.: Über Veränderungen des Stoffwechsel nach chronischer Morphinzufuhr. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 92, 68–96 (1922).
— Pentamethylentetrazol (Cardiazol). I. Mitteilung. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 116, 100–109 (1926).
Himmelsbach, C. K., G. H. Gerlich and E. J. Stanton: A method for testing addiction, tolerance and abstinence in the rat. Results of its application to several morphine alkaloids. J. Pharmacol. exp. Ther. 53, 179–188 (1935).
—, and L. F. Small: Clinical studies of drug addiction. II. “Rossium” treatment of drug addiction. Publ. Hlth Rep. Suppl. No. 125 (1937).
Hoff, H., U. O. Kauders: Über chronische experimentelle Medinalintoxikation. Z. ges. Neurol. Psychiat. 103, 176–184 (1926).
Hofmann, A.: Inaug. Diss. Gießen 1906.
Hotovy, R.: Zur Pharmakologie des Belladonnins. Arzneimittel-Forsch. 4, 287–292 (1954).
Hubbard, T. F., and L. R. Goldbaum: The mechanism of tolerance to thiopental in mice. J. Pharmacol. exp. Ther. 97, 488–491 (1949).
Ingram, W. R., and S. W. Ranson: Bulbocapnine. Effect of animals with lesions of the central nervous system. A. M. A. Arch. Neurol. Psychiat. 31, 987–1006 (1934).
Irwin, S., and M. H. Seevers: Comparative study of regular and N-allylnormorphine induced withdrawal in monkeys addicted to morphine, 6-methyldihydromorphine, Dromoran, methadone and ketobemidone. J. Pharmacol. exp. Ther. 106, 397 (1952).
— M. Slabok, P. L. Debiase and W. M. Govier: Perphenazine (Trilafon), a new potent tranquilizer and antiemetic: I. Behavior profile, acute toxicity and behavioral mode of action. Arch. int. Pharmacodyn. 118, 358–374 (1959).
Isbell, H., and H. F. Fraser: Addiction to analgesics and barbiturates. Pharmacol. Rev. 2, 355–397 (1950).
— A. Wikler, N. B. Eddy, J. L. Wilson and C. F. Moran: Tolerance and addiction liability of 6-dimethylamino-4,4-diphenyl-heptanone-3 (methadon). J. Amer. med. Ass. 135, 888 bis 894 (1947).
Jellinek, ST.: Elektropathologische Versuche mit Gleichstrom. Med. Klin. 1920, Nr. 44, S. 1128; zit. bei Schilf.
Jenney, E. H., and C. C. Pfeiffer: Ann. N. Y. Acad. Sci. 64, 679 (1956); zit. bei Mitchell and Keasling.
Jervis, G. A.: Studies on phenylpyruvic oligophrenia. The position of the metabolic error. J. biol. Chem. 169, 651–656 (1947).
— Excretion of phenylalanine and derivatives in phenylpyruvic oligophrenia. Proc. Soc. exp. Biol. (N. Y.) 75, 83–86 (1950).
— Phenylpyruvic oligophrenia deficiency of phenylalanine-oxidizing system. Proc. Soc. exp. Biol. (N. Y.) 82, 514–515 (1953).
— R. J. Block, D. Bolling and E. Kanze: Chemical and metabolic studies on phenylalanine. II. The phenylalanine content of the blood and spinal fluid in phenylpyruvic oligophrenia. J. biol. Chem. 134, 105–113 (1940).
Joël, E.: Beiträge zur Pharmakologie der Körperstellung und der Labyrinthreflexe. XIII. Mitteilung. Haschisch. Pflügers Arch. ges. Physiol. 209, 526–536 (1925).
—, u. A. Ettinger: Zur Pathologie der Gewöhnung. III. Mitteilung: Experimentelle Studien über Morphingewöhnung. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmakol. 115, 334 bis 350 (1926).
Kadoyama, Ch.: Wirkung des Harmans auf das Zentralnervensystem. Tôkohu J. exp. Med. 17, 1–9 (1931); ref. Ber. ges. Physiol. 61, 818; zit. bei A. G. Beer (1939a).
Kaelber, W. W., and R. J. Joynt: Tremor production in cats given chlorpromazine. Proc. Soc. exp. Biol. (N. Y.) 92, 399–402 (1956).
Kaufman, M. R., u. E. A. Spiegel: Experimentelle Analyse der Beeinflussung katatoner Zustände durch Einatmen von Kohlensäure-Sauerstoffmischungen. Z. ges. Neurol. Psychiat. 127, 312–320 (1930).
Kaymakcalan, S., and L. A. Woods: Response of morphine-tolerant dogs and rats to methimazole and/or nalorphine. Fed. Proc. 13, 373 (1954).
— — Nalorphine-induced “abstinence syndrome” in morphine-tolerant albino rats. J. Pharmacol. exp. Ther. 117, 112–116 (1956).
Keasling, H. H., E. G. Gross, F. A. D. Alexander, C. Hirschler and L. Marshall: The effect of chronic morphine administration on tooth pulp thresholds in dogs. J. Pharmacol. exp. Ther. 126, 345–348 (1959).
Keeser, E., H. A. Oelkers U. W. Raetz: Über das Schicksal des Morphins im Tierkörper. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 173, 622–632 (1933).
Kennedy, A.: The effect of cardiazol convulsions on the so-called“Bulbocapnine-Catatonia” in the monkey. J. Neurol. Psychiat. 2, 115–124 (1939).
Kennedy, W. P.: Sodium salt of C-C-cyclohexenylmethyl-N-methyl barbituric acid (evipan) anaesthesia in laboratory animals. J. Pharmacol. exp. Ther. 50, 347–353 (1934).
Kewitz, H., U. H. Reinert (unter Mitarbeit von G. Schaeffer U. F. Massberg): Zum Nachweis von Funktionsänderungen im Zentralnervensystem durch elektrisch und chemisch induzierte Krämpfe. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 215, 93–99 (1952).
Kobayashi, A.: Über die Morphingewöhnung und die dabei beobachtete erregende Wirkung des Morphins. Jap. J. med. Sci., Trans IV., Pharmacol. 4, 189 (1930); ref. Ber. Physiol. 57, 505.
Kobinger, W.: Förderung von Streckkrämpfen und experimentelle Katatonie. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 236, 123–124 (1959).
Koch, R.: Audiogene sowie durch Pentamethylentetrazol und Strychnin hervorgerufene Krämpfe bei adrenalektomierten Ratten. Arzneimittel-Forsch. 8, 90–92 (1958).
—, u. U. Hagen: Vergleichende toxikologische Untersuchungen an Cysteaminderivaten und entsprechenden Aminoalkoholen. Arch. int. Pharmacodyn. 109, 108–120 (1957).
Kohn, R., u. M. Jacobi: Untersuchungen über qualitative und quantitative Beziehungen zwischen Schlafmitteln und Analepticis. Arch. Naunyn-Schmiedeberg’s exp. Path. Pharmak. 179, 448–458 (1935).
Kok, D. J.: L’intoxication aigue par la bulbocapnine chez le chien. Proc. roy. Acad. Sci. Amst. 37, 357–361 (1934).
Komlos, E., u. I. Földes: Ausbildung bedingter Reflexe während Morphingewöhnung. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 229, 463–468 (1956).
Koopman, J.: Studies on morphinism. Arch. int. Pharmacodyn 29, 19–30 (1924).
Kornetsky, C., J. Cochin and E. Kammen: Protracted tolerance to morphine in the rat. Fed. Proc. 18, 411 (1958).
Kouzmanoff, S. P., and R. Tislow: Experimental states of catatonia elicited by bulbocapnine and some phenothiazine compounds. Fed. Proc. 17, 385 (1958).
Krause, F., U. H. de Jong: Über die Lokalisation einiger motorischer Erscheinungen bei der Bulbocapnin-Katatonie. Z. ges. Neurol. Psychiat. 133, 754–761 (1931).
Krisch, H., U. E. A. Spiegel: Sichtbarmachung latenter, experimentell hervorgerufener Tonusstörungen mit Bulbocapnin. Z. ges. Neurol. Psychiat. 122, 535–544 (1929).
Krueger, H., N. B. Eddy and M. Sumwalt: The pharmacology of the opium alkaloids. Publ. Hlth. Rep. Suppl. No 165, 1941.
Kun, E., and L. G. Abood: “In vivo” action of morphine, urethane and phenobarbital on the glycogen synthesis from glucose in the rat liver. Arch. int. Pharmacodyn. 80, 51–61 (1949).
Laffan, R. J., E. A. Swinyard and L. S. Goodman: Stimulus intensity, maximal electro-shock seizures, and potency of anticonvulsants in rats. Arch. int. Pharmacodyn. 111, 60–69 (1957).
Lambert, P.-A., S. Courvoisier et L. Julou: Notes sur l’activité neuroleptique d’un dérivé phénothiazine à propriété pure. Étude pharmacodynamique et clinique de la diméthyl-sulfamido-3[(Méthylsulfonyl-4″-Piperazino)3′Tropyl]-10 Phé;nothiazine (9.260 R. P.). Psychopharmacologia 2, 209–213 (1961).
Langer, H.: Über Heroinausscheidung und -gewöhnung. Biochem. Z. 45, 221–238 (1912).
Langley, J. N.: On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. J. Physiol. (Lond.) 33, 374–413 (1905).
—, and W. L. Dickinson: Pituri and nicotin. J. Physiol. (Lond.) 11, 265–306 (1890).
Laurence, D. R., and R. S. Stagey: The effect of methonium compounds on nicotine convulsions. Brit. J, Pharmacol. 7, 80–84 (1952).
Lending, M., L. B. Slobody and J. Mestern: Effect of prolonged convulsions on the blood-cerebrospinal fluid barrier. Amer. J. Physiol. 197, 465–468 (1959).
Lenke, D.: Narkosepotenzierende und analgetische Wirkung von l,4-Dipyrrolidino-2-butin. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 234, 35–45 (1958).
Lessin, A. W., and M. W. Parkes: The effects of reserpine and other agents upon leptazol convulsions in mice. Brit. J. Pharmacol. 14, 108–111 (1959).
Levy, B. M.: New method for rapid determination of lathyrogenic agents. Science 129, 720 (1959).
Lewin, L.: Untersuchungen über Banisteria Caapi Spr. (Ein südamerikanisches Rauschmittel). Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 129, 133–149 (1928).
Lewis, J. R.: The development of tolerance in rats to some new synthetic analgesics. J. Pharmacol. exp. Ther. 96, 31–37 (1949).
Liberson: Yale J. Biol. Chem. 17, 572 (1945); zit. bei Woodbury U. Swinyard (1947).
Lodin, Z., and K. Koloušek: The metabolism of methionine and methionine sulfoximine function of the central nervous system. XXth Internat. Physiol. Congr., Bruxelles, Abstr. of Comm. 583–584 (1956).
Loewe, S.: Studies on the pharmacology and acute toxicity of compounds with marihuana activity. J. Pharmacol. exp. Ther. 88, 154–161 (1946).
— Cannabiswirkstoffe und Pharmakologie der Cannabinole. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 211, 175–193 (1950).
Mac Kay, E. M.: The relation of acquired morphine tolerance to the adrenal cortex. J. Pharmacol. exp. Ther. 43, 51–60 (1931).
Maloney, A. H.: An analysis of the stimulant-depressant action of caffeine, coramine and metrazol (cardiazol) based on experimental data. Arch. int. Pharmacodyn. 52, 373–380 (1935).
Marshall, P. G., and D. K. Vallance: Anticonvulsant activity. Derivatives of succinimide, glutarimide, thiazolidinedione and methanol, and some miscellaneous compounds. J. Pharm. (Lond.) 6, 740–746 (1954).
Masuda, M., R. N. Budde and J. M. Dille: J. Amer. pharm. Ass. 27, 830 (1938); zit. bei Ch. M. Gruber and G. F. Keyser: J. Pharmacol. exp. Ther. 86, 186–196 (1946).
Matschulan, G.: Jahresrhythmen in Entwicklung und Verlauf der Morphingewöhnung und Entwölnung. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 186, 113–117 (1937a).
— Abhängigkeit der Morphingewöhnung und -entwöhnung von der Ernährimg. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 187, 230–233 (1937b).
Maynert, E. W., and G. I. Klingman: Acute tolerance to intravenous anesthetics in dogs. J. Pharmacol. exp. Ther. 128, 192–200 (1960).
—, and L. Losin: The metabolism of butabarbital (butisol) in the dog. J. Pharmacol. exp. Ther. 115, 275–282 (1955).
Mcquarrie, D. G., and E. Fingl: Hyperexcitability in mice following cessation of chronic administration of ethanol. Fed. Proc. 14, 369 (1955).
Mehl, W.: Addition der Wirkung von einigen Analepticis zu Medinal. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 151, 41–48 (1930).
Mellanby, E.: Diet and canine hysteria: Experimental production by treated flour. Brit. med. J. 2, 885–887 (1946).
— Further observations on the production of canine hysteria by flour treated with nitrogen trichloride (Agene process). Brit. med. J. 1947 II, 288/289.
Mellett, L. B., and L. A. Woods: The distribution and fate of morphine in the non-tolerant and tolerant monkey. J. Pharmacol. exp. Ther. 116, 77–83 (1956).
Melnick, D., and G. R. Cowgill: The toxicity of high-gliadin diets: Studies on the dog and on the rat. J. Nutr. 14, 401–418 (1937).
Merrit, H. H., and T. J. Putnam: A new series of anticonvulsant drugs testes by experiments on animals. A. M. A. Arch. Neurol. Psychiat. 39, 1003–1015 (1938).
Miller, G. H., and O. H. Plant: Effect of morphine and some other opium alkaloids on the muscular activity of the alimentary canal. II. Influence of continued administration of morphine and of withdrawal on the contractions of small intestines of dogs. J. Pharmacol. exp. Ther. 28, 241–249 (1926).
Mirsky, J. H., H. D. White and T. B. O’Dell: Central nervous system depressant effects of some indolylethylpyridines. J. Pharmacol. exp. Ther. 125, 122–127 (1959).
Mitchell, C. L., and H. H. Keasling: A comparison of three anticonvulsant testing methods. J. Pharmacol. exp. Ther. 128, 79–84 (1960).
Mode, A.: Über die physiologischen Eigenschaften des Bulbocapninum hydrochloricum. Diss. Berlin, 1892.
Moir, W. M.: The influence of age and sex on the repeated administration of sodium pentobarbital to albino rats. J. Pharmacol. exp. Ther. 59, 68–85 (1937).
M⊘ller-Nielsen, I., and K. Neuhold: The comparative pharmacology and toxicology of the trans-isomer of 2-chloro-9-(3′-dimethylaminopropylidene)-thiaxanthene, HCl (Chlorpro-thixene) = N714 trans and chlorpromazine. Acta pharmacol. (Kbh.) 15, 335–355 (1959).
Moran, T.: Lancet 1947II, 289, zit. bei Newell U. Mitarb. (1948).
Morgan, T. H.: Ann. N. Y. Acad. Sci. 21, 87 (1911); zit. bei Goldin U. Mitarb.
Mott, F. W., D. L. Woodhouse and F. A. Pickworth: Brit. J. Exper. Path. 7, 325 (1926); zit. bei E. J. Stanton: J. Pharmacol. exp. Ther. 57, 245–252 (1936).
Myers, H. B.: The effect of chronic morphine poisoning upon growth, the oestrus cycle and fertility of the white rat. J. Pharmacol. exp. Ther. 41, 317–323 (1931).
—, and J. B. Flynn: Effect of morphine in moderate doses upon growth of the white rat. Proc. Soc. exp. Biol. (N. Y.) 25, 786–787 (1928).
Neuner, A., u. H. Tappeiner: Über die Wirkung der Alkaloide von Peganum Harmala, insbesondere des Harmalins. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 35, 69–76 (1894).
Newell, G. W., T. C. Erickson, W. E. Gilson and C. A. Elvehjem: Effect of wheat gluten diet on the electroencephalograms of dogs. Proc. Soc. exp. Biol. (N. Y.) 65, 115–116 (1947a).
— — —S. N. Gershoff and C. A. Elvehjem: Role of “agenized” flour in the production of running fits. J. Amer. med. Ass. 135, 760–763 (1947b).
— S. N. Gershoff, F. H. Fung and C. A. Elvehjem: Effect of adiminstering agenized amino acids and wheat gluten to dogs. Amer. J. Physiol. 152, 637–644 (1948).
Nicholas, J. S., and D. H. Barron: The use of sodium amytal in the production of anesthesia in the rat. J. Pharmacol. exp. Ther. 46, 125–129 (1932).
Nieschulz, O., I. Hoffmann U. K. Popendiker: Pharmakolohische Untersuchungen über N-Methyl-piperazinyl-N′-propyl-phenothiazin. Arzneimittel-Forsch. 8, 199–210 (1958).
Nyáry, A. V.: Die krampfhemmende Wirkung der Hypnotica. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 165, 504–515 (1932).
Oettel, H., U. A. Krautwald: Über chronische Schlafmittelvergiftung. Klin. Wschr. 16, 299–300 (1937).
Ohkawa, J.: Einige Versuche über den Kohlehydratstoffwechsel beim morphingewohnten Kaninchen. Mitt. med. Akad. Kioto 28, 895 (1940); ref. Ber. Physiol. 121, 429.
Orahovats, P. D., C. A. Winter and E. G. Lehman: The effect of N-allylnormorphine upon the development of tolerance to morphine in the albino rat. J. Pharmacol. exp. Ther. 109, 413–416 (1953).
— — — and L. Flataker: Comparative studies of 6-substituted delta6-desoxymorphines and morphine with special reference to 6-methyl-delta6-desoxymorphine. J. Pharmacol. exp. Ther. 114, 100–109 (1955).
Orloff, M. J., H. L. Williams and C. C. Pfeiffer: Timed intravenous infusion of metrazol and strychnine for testing anticonvulsant durgs. Proc. Soc. exp. Biol. (N. Y.) 70, 254–257 (1949).
Pace, J., and E. E. Mc Dermott: Methionine sulfoximine and some enzyme systems involving glutamine. Nature (Lond.) 169, 415–416 (1952).
P’an, S. Y., R. Carioto, E. Timmens and J. F. Gardocki: Tremorine antagonism studies with a new anticholinergic agent, oxyphencyclimine. Arch. int. Pharmacodyn. 120, 222–228 (1959).
Paterson, A. S., and C. P. Richter: Action of scopolamine and carbon dioxide on catalepsy produced by bulbocapnine. A. M. A. Arch. Neurol. Psychiat. 29, 231–240 (1933).
Peters, F.: Pharmakologische Untersuchungen über Corydalisalkaloide. Naunyn-Schmiede-berg’s Arch. exp. Path. Pharmak. 51, 130–174 (1904).
Peters, J. J., A. R. Vonderahe and P. A. Palmisano: The influence of pentylenetetrazol, strychnine and curare on the electrical activity of the brain and cord of the salamander. J. Pharmacol. exp. Ther. 114, 225–230 (1955).
— — and T. H. Powers: Comparative effects of some convulsant drugs on the behavior and electrical activity of the nervous and muscular system of the salamander. J. Pharmacol. exp. Ther. 123, 28–34 (1958).
Phatak, N. M., and N. A. David: Effects of hydergine (CCK/179) on the modification of tolerance to morphine and 1-isomethadone hyperglycemia in rabbits. J. Pharmacol. exp. Ther. 109, 139–147 (1953).
— J. Maloney and N. David: Use of hyperglycemic response for estimating addiction poten-tialities of analgesic compounds. Fed. Proc. 7, 249 (1948).
Pierce, I. H., and O. H. Plant: Excretion of morphine in dogs made tolerant by long continued administration of moderate doses. J. Pharmacol. exp. Ther. 39, 265–266 (1930).
— — Studies of chronic morphine poisoning in dogs. IV. Excretion of morphine in tolerant and non-tolerant animals. J. Pharmacol. exp. Ther. 46, 201–228 (1932).
Plant, O. H., and I. H. Pierce: General symptoms and behavior of dogs during morphine tolerance and withdrawal. J. Pharmacol. exp. Ther. 31, 210–211 (1927).
— — — Studies of chronic morphine poisoning in dogs. I. General symptoms and behavior during addiction and withdrawal. J. Pharmacol. exp. Ther. 33, 329–357 (1928).
— — Studies of chronic morphine poisoning in dogs. V. Recovery of morphine from tissues of tolerant and non-tolerant animals. J. Pharmacol. exp. Ther. 49, 432–449 (1933).
—, and D. Slaughter: Effects of dinitrophenol on the excretion of morphine in tolerant and non-tolerant dogs (Preliminary report). J. Pharmacol. exp. Ther. 54, 157–158 (1935).
— — Studies of chronic morphine poisoning in dogs. VI. Effect of increasing tissue oxidations by dinitrophenol on the excretion of morphine in tolerant and non-tolerant dogs. J. Pharmacol. exp. Ther. 58, 417–427 (1936).
— — Studies of chronic morphine poisoning in dogs. VII. Effect of thyroid feeding on the excretion of morphine in tolerant and non-tolerant dogs. J. Pharmacol. exp. Ther. 62, 106–110 (1938).
Preziosi, P., and G. R. de Vleeschhouwer: Anti-“Tremorine” effects of the diethylamino-ethylester of monoethylphenylethylmalonate. Arch. int. Pharmacodyn. 120, 108–113 (1959).
Pulewka, P.: Über die relative Wirksamkeit türkischer Hanfpflanzen. Naunyn-Schmiedeberg–s Arch. exp. Path. Pharmak. 211, 278–286 (1950).
Radomski, J. L., and G. Woodard: Pharmacological studies on the causative agent of canine hysteria. J. Pharmacol. exp. Ther. 95, 429–437 (1949).
— — and A. J. Lehman: J. Nutr. 36, 15 (1948); zit. bei Bentley U. Mitarb. (1949a).
Radouco, C., Ed. Frommel, Ph. Gold, G. Greder, D. Melkonian, S. Radouco, L. Strass-berger, F. Vallette et M. Ducommun: Étude physio-pathologique de l’action du pentaméthylènetétrazol (cardiazol). Deuxiéme mémoire. Arch. int. Pharmacodyn. 92, 13–38 (1952a).
— — — G. Greder, D. Melkonian, S. Radouco, L. Strassberger, F. Vallette et M. Ducommun: La physiologie de l’épilepsie électrique expérimentale. Arch. int. Pharmacodyn. 92, 129–162 (1952b).
Ravdin, I. S., D. L. Drabkin and A. E. Bothe: J. Lab. clin. Med. 16, 561 (1930) ; zit. bei Ch. M. Gruber and G. F. Keyser: J. Pharmacol. exp. Ther. 86, 186–196 (1946).
Reinhard, J. F., O. J. Plekss and J. V. Scudi: Some pharmacological actions of amphenidone, a new psychotherapeutic drug. Proc. Soc. exp. Biol. (N. Y.) 104, 480–482 (1960).
Rentz, E., U. D. N. Kesarbani: Gewöhnung des Meerschweinchendarms an Morphin. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 198, 107–113 (1941).
Reuse, J. J.: A propos des propriétés antinicotiniques des certains dérivés de la thiodiphényl-amme. Arch. int. Pharmacodyn. 89, 117–121 (1952).
— Effects de la réserpine sur les réponses circulatoires et respiratoires de doses convulsivantes de pentétrazol et de bémégride chez le Lapin. Modifications par l’atropine et la respiration artificielle. C. R. Soc. Biol. (Paris) 153, 1479–1482 (1959).
Richter, C. P., and A. S. Paterson: Bulbocapnine catalepsy and the grasp reflex. J. Pharmacol. exp. Ther. 43, 677–691 (1931).
Rickards, J. C., G. E. Boxer and C. C. Smith: Studies on the distribution and metabolism of methadone in normal and tolerant rats by a new colorimetric method. J. Pharmacol. exp. Ther. 98, 380–391 (1950).
Ridder, C: Pentamethylentetrazol (Cardiazol). IV. Mitteilung: Wird Cardiazol in der Leber entgiftet? Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 120, 126–128 (1927).
Ro: Jap. J. med. Sci., IV. Pharmacology 9, 59 (1935); zit. bei N. M. Phatak, J. Maloney and N. David: Fed. Proc. 7, 249 (1948).
Rothlin, E., u. A. Cerletti: Über einige pharmakologische Untersuchungen an Mäusen mit congenitaler Drehsucht. Helv. physiol. pharmacol. Acta 10, 319–327 (1952).
Rudberg, T.: Occurrence of the “Waltzing syndrome” in mice after administration of amino-dipropionitrile. Acta pharmacol. (Kbh.) 13, 233–239 (1957).
— Effects of atropine on “Waltzing syndrome” in mice after iminodipropionitrile. Acta physiol. scand. 42, 199–203 (1958).
Rübsamen, W.: Experimentelle Untersuchungen über die Gewöhnung an Morphin. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 59, 227–244 (1908).
Sacchi, U., A. Brusa e G. Gianniotti: Boll. Soc. ital. Biol. sper. 32, 438 (1956); zit. bei C. Fazio and U. Sacchi (1957).
Sacchi, U., e G. Gianniotti: Boll. Soc. ital. Biol. sper. 32, 175 und 177 (1956); zit. bei C. Fazio and U. Sacchi (1957).
Sasaki, T., u. I. Otsuka: Beiträge zur Kenntnis der chemischen Konstitution und der biologischen Wirkung. Über amyostatische Gifte. I. Mitt. J. Biochem. (Tokyo) 12, 429–458 (1930); ref. Berg. ges. Physiol. 60, 506.
—, u. H. Ueda: Beiträge zur Kenntnis des Zusammenhanges zwischen chemischer Konstitution und biologischer Wirkung. II. Biochem. Z. 232, 260–268 (1931); ref. Ber. ges. Physiol. 62, 215.
Sato, M.: Über die Entstehung der Schwimm- und Laufbewegungen durch das Harman und seine Drivate. Tôhoku J. exp. Med. 26, 161–163 (1935); ref. Ber. ges. Physiol. 89, 201; zit. bei A. G. Beer (1939a).
Scarborough, E. M.: The influence of thyroid feeding on chronic morphine poisoning. J. Pharmacol. exp. Ther. 27, 421–429 (1926).
Scott, C. C., and K. K. Chen: The action of l,l-diphenyl-l-(dimethylaminoisopropyl)-butanone-2, a potent analgesic agent. J. Pharmacol. exp. Ther. 87, 63–71 (1946).
— — — K. G. Kohlstaedt, E. B. Robbins and F. W. Isbell: Further observations on the pharmacology of “dolophine” (methadon, Lilly). J. Pharmacol. exp. Ther. 91, 147–156 (1947b).
Scott, C. C., K. G. Kohlstaedt, E. B. Robbins and F. W. Isbell: Further observations on the pharmacology of dolophine. Fed. Proc. 6, 370 (1947a).
Schaltenbrand, G.: Über die Bewegungsstörungen bei akuter Bulbocapninvergiftung. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 103, 1–16 (1924).
— Beiträge zur Pharmakologie der Körperstellung und der Labyrinthreflexe. XIV. Mitteilung. Die Wirkung des Bulbocapnins auf unverletzte Katzen. Pflügers Arch. ges. Physiol. 209, 623–642 (1925a).
— Beiträge zur Pharmakologie der Körperstellung und der Labyrinthreflexe. XV. Mitteilung. Wirkung des Bulbocapnins auf Rückenmarks- und decerebrierte Katzen. Pflügers Arch. ges. Physiol. 209, 643–652 (1925b).
— Beiträge zur Pharmakologie der Körperstellung und der Labyrinthreflexe. XVII. Mitteilung. Die Wirkimg der Bulbocapnins auf Katzen mit Cortexverletzungen. Versuch einer Lokalisation der Symptome, die bei Bulbocapninvergiftung unverletzter Tiere entstehen. Pflügers Arch. ges. Physiol. 209, 664–674 (1925c).
— Die Beziehungen der extrapyramidalen Symptomenkomplexe zu den Lage- und Bewegungsreaktionen, zum motorischen Haushalt und zu den Stammganglien. Dtsch. Z. Nervenheilk. 108, 209–245 (1929).
— Buchbesprechung zu: H. de Jong et H. Baruk: La Catatonie Expérimentale par la Bulbo-capnine. Paris: Masson et Cie. 1931. — Dtsch. Z. Nervenheilk. 124, 307–311 (1932).
—, and S. Cobb: Brain 53, 449 (1931); zit. bei J. N. Voss (1940).
Schaumann, O.: Morphin und morphinähnlich wirkende Verbindungen. Handb. d. exper. Pharmakol., Ergänzungswerk, 12. Band, 1957.
Schilf, E.: Über experimentelle Erzeugung epileptischer Anfälle durch dosierte Starkstromenergie. Einfluß von Maßnahmen pharmakologischer, chirurgischer und serologischer Art auf die künstlich erzeugte Epilepsie. Z. ges. exp. Med. 28, 127–143 (1922).
Schlichtegroll, A. von: Zentrale und periphere Dämpfungswirkungen in der Reihe der Thiophenylpyridylamin-Derivate. Arzneimittel-Forsch. 8, 489–503 (1958).
Schmidt, C. F., and A. E. Livingston: The action of morphine on the mammalian circulation. J. Pharmacol. exp. Ther. 47, 411–441 (1933a).
— — The relation of dosage to the development of tolerance to morphine in dogs. J. Pharmacol. exp. Ther. 47, 443–471 (1933b).
Schoen, R.: Beiträge zur Pharmakologie der Körperstellung und der Labyrinthreflexe. XXII. Mitteilung: Hexeton und Cardiazol. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 113, 257–274 (1926).
Schuebel, K., u. W. Gehlen: Vergleichende Untersuchungen über atmungserregende Pharmaka am morphinvergifteten Kaninchen. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 133, 295–316 (1928).
Seevers, M. H.: Addiction potentialities of morphine, codeine, heroine and dilaudid in the monkey. J. Pharmacol. exp. Ther. 51, 141–142 (1934).
— Opiate addiction in the monkey. L Method of study. J. Pharmacol. exp. Ther. 56, 147–156 (1936a).
— Opiate addiction in the monkey. II. Dilaudid in comparison with morphine, heroine and codaine. J. Pharmacol. exp. Ther. 56, 157–165 (1936b).
— Animal experimentation in studying addiction to the new synthetics. Ann. N. Y. Acad. Sci. 51, 98–108 (1948).
— Adaptation to narcotics. Fed. Proc. 13, 672–684 (1954).
—, and A. L. Tatum: Chronic experimental barbital poisoning. J. Pharmacol. exp. Ther. 42, 217–231 (1931).
—, and L. A. Woods: The phenomena of tolerance. Amer. J. Med. 14, 546–557 (1953).
Shideman, F. E.: Effects of morphine and its derivatives on intermediary metabolism. IV. The influence of chronic morphine and heroin poisoning on the oxygen consumption of dog, rat and mouse skeletal muscle. J. Pharmacol. exp. Ther. 86, 242–247 (1946).
—, and H. T. Johnson: Acute vascular tolerance to morphine, demerol. and 1,1-diphenyl-l-(dimethylamino-isopropyl)butanone-2 (amidone) in the dog. Fed. Proc. 6, 371–372 (1947).
— — Acute vascular tolerance to morphine, isonipecaine (demerol), and methadon (amidone) in the dog. J. Pharmacol. exp. Ther. 92, 414–420 (1948).
— A. R. KELLY and B. J. Adams: Blood levels of thiopental (Pentothal) following repeated intravenous administration to the dog. Fed. Proc. 7, 255 (1948).
Silver, M. L.: Anat. Rec. 100, 78 (1948); zit. bei Silver U. Pollock.
— R. E. Johnson, R. M. Kark, J. R. Klein, E. P. Monahan and S. S. Zevin: White bread and epilepsy in animals. J. Amer. med. Ass. 135, 757–760 (1947c).
— E. P. Monahan and J. R. Klein: Canine epilepsy caused by flour bleached with nitrogen trichloride (agene). II. Role of amino acids. Proc. Soc. exp. Biol. (N. Y.) 66, 410–412 (1947b).
Silver, M. L., and G. H. Pollock:: Pôle of carbon dioxide and of the hindbrain in agene-induced canine epilepsy. Amer. J. Physiol. 154, 439–442 (1948).
— S. S. Zevin, R. M. Karrk and R. E. Johnson: Canine epilepsy caused by flour bleached with nitrogen trichloride (agene). I. Experimental method. Proc. Soc. exp. Biol. (N. Y.) 66, 408–409 (1947a).
Smith, R. G.: The sequence of events in the excitation of the respiratory center by caffeine and some other convulsants. J. Pharmacol. exp. Ther. 33, 147–165 (1928).
Spiegel, E.: Bulbocapnine-benzedrine antagonism. J. Pharmacol. exp. Ther. 63, 438–442 (1938).
Spiegel, E. A.: Quantitative determination of the convulsive reactivity by electric stimulation of the brain with the skull intact. J. Lab. clin. Med. 22, 1274–1276 (1937).
— Zur Pharmakologie der zentralen Tonusinnervation. Dtsch. Z. Nervenheilk. 124, 104–116 (1932).
—, and E. G. Szekely: Prolonged stimulation of the head of the caudate nucleus. A. M. A. Arch. Neurol. 4, 67–77 (1961).
Stanton, E. J.: Dihydromorphinone hydrochloride (dilaudid): its tranquilizing potency, respiratory depressant effects and addiction liability, as tested on the rat. J. Pharmacol. exp. Ther. 56, 252–263 (1935).
— Addiction and tolerance to barbiturates? The effect of daily administration and abrupt withdrawal of phenobarbital-sodium and pentobarbital-sodium in the albino rat. J. Pharmacol. exp. Ther. 57, 245–252 (1936).
— Insulin treatment of morphine abstinence symptoms. J. Pharmacol. exp. Ther. 60, 387 to 395 (1937).
Stein, W. H., and S. Moore: The free amino acids of human blood plasma. J. biol. Chem. 211, 915–926 (1954).
Stender, O., U. C. Amsler: Beiträge zur Kenntnis der Morphingewöhnung. Arch. exp. Path. Pharmakol. 160, 195–204 (1931).
Stern, P., u. D. Mitrović-Kocić: Pharmakologische Analyse der Bulbocapnin-Katalepsie an der Maus. Arch. int. Pharmacodyn. 116, 489–498 (1958).
— D. Ratković and Ž. Fuks: Pharmacological influences on intentional tremor. Arch. int. Pharmacodyn. 130, 1–8 (1961).
Stille, G., u. I. Brunckow: Die ganglioplegische Wirkung von 3-Alkylaminoalkyl-Hydantoine Arzneimittel-Forsch. 4, 723–725 (1954).
Stone, C. A., K. L. Meckelnburg and M. L. Torchiana: Antagonism of nicotine-induced convulsions by ganglionic blocking agents. Arch. int. Pharmacodyn. 117, 419–434 (1958).
Stumpf, CH.: Die Wirkung des Nicotin auf die Hippocampustätigkeit des Kaninchens. Naunyn-Schmiedeberg—s Arch. exp. Path. Pharmak. 235, 421–436 (1959).
Sung, Chen-Yu, and E. L. Way: Studies on the fate of d,l-methadone in rats made tolerant to the compound. J. Pharmacol. exp. Ther. 101, 34 (1951).
— — and K. G. Scott: Studies on the relationship of metabolic fate and hormonal effects of D,L-methadone to the development of drug tolerance. J. Pharmacol. exp. Ther. 107, 12–23 (1953).
Swanson, E. E., M. M. Weaver and K. K. Chen: Amer. J. Med. Sci. 193, 246 (1937); zit. bei Ch. M. Gruber and G. F. Keyser: J. Pharmacol. exp. Ther. 86, 186–196 (1946).
Swinyard, E. A.: Validity of laboratory anticonvulsant tests for predicting antiepileptic potency and specifity. Fed. Proc. 6, 376 (1947).
— Laboratory assays of clinically effective antiepileptic drugs. J. Amer. pharm. Ass. 38, 201–204 (1949a).
— Effect of extracellular electrolyte depletion on brain electrolyte pattern and electroshock seizure threshold. Amer. J. Physiol. 156, 163–169 (1949b).
— W. C. Brown and L. S. Goodman: Comparative assays of antiepileptic drugs in mice and rats. J. Pharmacol. exp. Ther. 106, 319–330 (1952).
— L. Chin and E. Fingl: Withdrawal hyperexcitability following chronic administration of meprobamate to mice. Science 125, 739–741 (1957).
—, and L. S. Goodman: Laboratory assay of anticonvulsant potency of some hydantoinates. Fed. Proc. 5, 205–206 (1946).
Szerb, J. C., and D. H. Mc Curdy: Concentration of morphine in blood and brain after intravenous injection of morphine in non-tolerant. tolerant and neostigmine-treated rats. J. Pharmacol. exp. Ther. 118, 446–450 (1956).
Tanabe, T., and E. J. Cafruny: Adrenal hypertrophy in rats treated chronically with morphine. J. Pharmacol. exp. Ther. 122, 148–153 (1958).
Tartler, O. P.: Über den Antagonismus und Synergismus zwischen einigen Analepticis und Medinal. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmakol. 143, 65–78 (1929).
Tatum, A. L., K. H. Collins and M. H. Seevers: Further observations in experimental chronic morphinism. J. Pharmacol. exp. Ther. 31, 213–214 (1927).
— M. H. Seevers and K. H. Collins: Morphine addiction and its physiological interpretation on experimental evidence. J. Pharmacol. exp. Ther. 36, 447–475 (1929).
Tedeschi, D. H., E. A. Swinyard and L. S. Goodman: Effects of variations in stimulus intensity on maximal electroshock seizure pattern, recovery time, and anticonvulsant potency of phenobarbital in mice. J. Pharmacol. exp. Ther. 116, 107–113 (1956).
— R. E. Tedeschi, L. Cook, P. A. Mattis and E. J. Fellows: The neuropharmacology of trifluoperazine: a potent psychotherapeutic agent. Arch. int. Pharmacodyn. 122, 129–143 (1959).
Ten Cate, J., et D. W. Swijgman: Localisation de l’origine des convulsions produites par le cardiazol et la coramine. Arch. int. Pharmacodyn. 70, 293–306 (1945).
Thienes, C. H., and L. E. Detrick: Morphine addiction and withdrawal: Effect of calcium therapy and tissue hydration. J. Pharmacol. exp. Ther. 66, 36 (1939).
Thuillier, J., A. Burger et P. Mouille: Contribution à l’étude du syndrome motéur pro-vorqué chez la souris par l’amino-dipropionitrile (souris tournantes). C. R. Soc. Biol. (Paris) 147, 1052–1055 (1953).
— — Contributation à l’étude du syndrome moteur provoqué chez la couris par l’amino-dipropionitrile (souris tournantes). Experientia (Basel) 10, 223–224 (1954).
—, et H. Nakajima: Action comparée des drogues psychotropes sur les «souris tournantes» provoquées par l’imino-β,β′-dipropionitrile. In: Psychotropic Drugs. p. 136–158. Elsevier Publishing Company 1957.
Toman, J. E. P.: Neuropharmacologic considerations in psychic seizures. Neurology 1, 444–460 (1951).
—, and L. S. Goodman: Anticonvulsants. Physiol. Rev. 28, 409–432 (1948).
Torda, C.: Ammonium ion content and electrical activity of the brain during preconvulsive and convulsive phases induced by various convulsants. J. Pharmacol. exp. Ther. 107, 197–203 (1953).
Tripod, J., H. J. Bein and R. Meier: Characterization of central effects of serpasil (reserpin, a new alkaloid of rauwolfia serpentina B.) and of their antagonistic reactions. Arch. int. Pharmacodyn. 96, 406–423 (1953).
Udenfriend, S., and S. P. Bessman: The hydroxylation of phenylalanine and antipyrine in phenylpyrurc oligophrenia. J. biol. Chem. 203, 961–966 (1953).
—, and J. R. Cooper: The enzymatic conversion of phenylalanine to tyrosine. J. biol. Chem. 194, 503–511 (1952).
Voss, J.: Pentamethylentetrazol (Cardiazol). III. Mitteilung: Über die Wirkung von Cardiazol bei peroraler Applikation. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 118, 259–266 (1926).
Voss, J. N.: Über das Verhalten halbseitig großhirnloser Tiere und Bulbocapnin in mittleren Gaben. Pflügers Arch. ges. Physiol. 243, 496–504 (1940).
Wachtel, C.: Nachweis und Bestimmung des Morphins und anderer Alkaloide in tierischen Ausscheidungen und Organen. Biochem. Z. 120, 265–283 (1921).
Wagner, J. R., and C. A. Elvehjem: J. Nutr. 28, 431 (1944); zit. bei Newell U. Mitarb. (1948).
Waisman, H. A., H. L. Wang, H. Herlow and R. R. Sponholz: Experimental phenylketonuria in the monkey. Proc. Soc. exp. Biol. (N. Y.) 101, 864–865 (1959).
— —G. Palmer and H. F. Harlow: Phenylketonuria in infant monkeys. Nature (Lond.) 188, 1124–1125 (1960).
Wastl, H.: Influence of various salts on metrazol reactions. Arch. int. Pharmacodyn. 66, 397–408 (1941).
Watt, J. M.: The influence of cardiazol on the cardio-vascular system and its utility in cases of circulatory failure. Arch. int. Pharmacodyn. 36, 225–232 (1936).
Wawzonek, S., I. V. Poseti, R. S. Shepard and L. G. Wiedenmann: Epiphysal plate lesions, degenerative arthritis, and dissecting aneurysm of the aorta produced by aminonitriles. Science 121, 63–65 (1955).
Way, E. L., Chen-Yu Sung and J. M. Fujimoto: The effect of adrenalectomy on the development of tolerance to morphine and methadone. J. Pharmacol. exp. Ther. 110, 51–52 (1954).
Weger, P., U. C. Amsler: Beschleunigung der Gewöhnung an Morphin bzw. Verzögerung der Entwöhnung davon durch Vitamin D-Mangel. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 183, 9–12 (1936a).
— — Weiteres zum Problem der Gewöhnung am Morphin. Naunyn-Schmideberg’s Arch. exp. Path. Pharmak. 181, 489–493 (1936b).
Werner, H. W., and A. L. Tatum: A comparative study of the stimulant analeptics Picrotoxin, metratzol and coramine. J. Pharmacol. exp. Ther. 66, 260–278 (1939).
Widlocher, D., H. Nakajima et J. Thuillier: Action des monoéthylamide (LAE) et diéthylamide (LSD) de l’acide lysergique sur le comportement de la Souris tournante provoquée par l’imino-β,β′-dipropionitrile. C. R. Soc. Biol. (Paris) 151, 668–670 (1957).
Wienke, H.: Zur Frage der Beeinflussung der Elektro- und Cardiazolkrampfschwellen durch vegetative Nervengifte. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 217, 312 (1953).
Wikler, A.: Hindlimb reflexes in chronic spinal dogs during a cycle of morphine addiction. Fed. Proc. 4, 141 (1945).
— Reactions of chronic totally decorticated dogs during a cycle of morphine addiction. Fed. Proc. 5, 212–213 (1946).
—, and K. Frank: Tolerance and physical dependence in intact and chronic spinal dogs during addiction to 10820 (4,4-diphenyl-6-dimethylamino-heptanone-3). Fed. Proc. 6, 384 (1947).
— — Hindlimb reflexes of chronic spinal dogs during cycles of addiction to morphine and methadon. J. Pharmacol. exp. Ther. 94, 382–400 (1948).
Windle, W. F., J. Cammermeyer, E. R. Feringa, J. Joralemon, J. O. Smart and M. P. Mc Quillen: Tremor in African green monkeys. Fed. Proc. 15, 202 (1956).
Winiwarter, F.: Über die Wirkung von Schlafmitteln, Antipyreticis und Analepticis auf normale und großhirnlose Tauben. Arch. exp. Path. Pharmak. 185, 95–101 (1937).
Winter, C. A., and L. Flataker: Studies on heptazone (6-morpholino-4,4-diphenyl-3-heptanone hydrochloride) in comparison with other analgesic drugs. J. Pharmacol. exp. Ther. 98, 305–317 (1950).
Wirth, W.: Zur pharmakologischen Wirkung von Promazin. Arzneimittel-Forsch. 8, 507–511 (1958).
— R. Gösswald, U. Hörlein, K.-H. Risse U. H. Kreiskott: Zur Pharmakologie acylierter Phenothiazin-Derivate. Arch. int. Pharmacodyn. 115, 1–31 (1958).
— — u. W. Vater: Zur Pharmakolgie acylierter Phenothiazin-Derivate. Arch. int. Pharmacodyn. 123, 78–114 (1959).
Wolf, J.: Versuche zum Nachweis exzitierender Wirkungen narkotischer Stoffe und Rauschgifte mit Hilfe des Elektroschockverfahrens. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 214, 14–28 (1951).
Wolf-Heidegger, G., F. Schürmann U. J. Meier: Erbliche Drehbewegungen bei Mäusen. Verh. Schweiz. Naturforsch. Ges. 1941, 205.
Woodbury, D. M., R. E. Hurley, N. G. Lewis, M. W. Mc Arthur, W. W. Copeland, J. F. Kirschvink and L. S. Goodman: Effect of thyroxine, thyroidectomy and 6-n-propyl-2-thiouracil on brain function. J. Pharmacol. exp. Ther. 106, 331–340 (1952).
Woodbury, J. W., J. Simons, R. Evans, T. Y. Burton and J. E. P. Toman: Effect of di-phenylhydantoin on recovery of various central nervous functions following maximal electroshock seizures in cats. Amer. J. Physiol. 155, 479–480 (1948).
Woodbury, L. A., and V. D. Davenport: Design and use of a new electroshock apparatus, and analysis of factors altering seizure threshold and pattern. Arch. int. Pharmacodyn. 92, 97–107 (1952).
—, and E. A. Swinyard: Energy requirements for the electrical production of seizures. Fed. Proc. 6, 230 (1947).
Woods, L. A., J. B. Wyngaarden and M. H. Seevers: The addiction potentialities of l,l-diphenyl-l-(dimethylaminopropyl)-butanone-2 (amidone) in the monkey. Fed. Proc. 6, 387 (1947a).
— — — Addiction potentialities of l,l-diphenyl-l-(beta-dimethylaminopropyl)-butanone-2-hydrochloride (amidone) in the monkey. Proc. Soc. exp. Biol. (N. Y.) 65, 113–114 (1947b).
Woolfe, G., and A. D. Mc Donald: Evaluation of the analgesic action of pethidine hydrochloride (demerol). J. Pharmacol. exp. Ther. 80, 300 (1944) ; zit. bei H. Isbell, A. Wikler, N. B. Eddy, J. L. Wilson and C. F. Moran: J. Amer. med. Ass. 135, 888–894 (1947).
Woolley, D. E., P. S. Timiras, M. R. Rosenzweig, D. Krech and E. L. Bennett: Sex and strain differences in electroshock convulsions of the rat. Nature (Lond.) 190, 515–516 (1961).
Zauder, H. L.: The effect of certain analgesic drugs and adrenal cortical hormones on the brain of normal and hypophysectomized rats as measured by the thiobarbituric acid reagent. J. Pharmacol. exp. Ther. 101, 40–46 (1951).
— The effect of prolonged morphine administration on the in vivo and in vitro conjugation of morphine in rats. J. Pharmacol. exp. Ther. 104, 11–19 (1952).
Zetler, G.: Substanz P, ein Polypeptid aus dem Darm und Gehirn mit depressiven, hyper-algetischen und Morphin-antagonistischen Wirkungen auf das Zentralnervensystem. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 228, 513–538 (1956).
— Der Harmin-Tremor und seine Antagonisten. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 231, 34–54 (1957).
— Versuche zur antikonvulsiven Wirksamkeit des Polypeptids SubstanzP. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 237, 11–16 (1959).
— K. Mahler U. F. Daniel: Versuche zu einer pharmakologischen Differenzierung katalep-tischer Wirkungen. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 238, 486–501 (1960).
—, u. E. Moog: Die Bulbocapnin-Katatonie, ihre Synergisten und Antagonisten. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 232, 442–458 (1958).
— W. Müller u. I. Warm: Jactatio capitis, eine pharmakologisch ausgelöste Stereotypie der Maus. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 237, 247–263 (1959).
Zipf, K., W. A. Windschus U. F. Kokoschka: Zur Wirkung von Cardiazol, Coramin, Hexeton, Strychnin und Ikoral gegenüber Narkotica. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 185, 113–124 (1937).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1962 Springer-Verlag oHG. Berlin · Göttingen · Heidelberg
About this chapter
Cite this chapter
Stumpf, C. (1962). Pharmakologische Methoden. In: Stumpf, C., Petsche, H., Eichler, O. (eds) Zentralnervensystem. Handbuch der Experimentellen Pharmakologie, vol 16 / 7. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-48100-0_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-48100-0_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-48101-7
Online ISBN: 978-3-642-48100-0
eBook Packages: Springer Book Archive